user

Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Hogben, C. [1 ]
Kouranos, V. [2 ]
Kokosi, M. [3 ]
Renzoni, E. A. [4 ]
Chua, F. [5 ]
Wells, A. U. [6 ]
Maher, T. M. [3 ]
Molyneaux, P. L. [5 ]
George, P. M. [7 ]
机构：
[1] Royal Brompton & Harefield NHS Fdn Trust, Interstitial Lung Dis Unit, London, England
[2] Royal Brompton Hosp, Interstitial Lung Dis, London, England
[3] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[4] Imperial Coll, Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[5] Royal Brompton & Harefield NHS Fdn Trust, London, England
[6] Royal Brompton Hosp, Resp, London, England
[7] Royal Brompton Hosp, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1635
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SINGLE CENTRE EXPERIENCE OF SWITCHING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS FROM PIRFENIDONE TO NINTEDANIB
    Rathnapala, A.
    Fries, A.
    Ruggiero, C.
    Ho, L. P.
    Hoyles, R. K.
    THORAX, 2016, 71 : A60 - A60
  • [2] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [3] Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
    Ogura, Takashi
    Taniguchi, Hiroyuki
    Azuma, Arata
    Inoue, Yoshikazu
    Kondoh, Yasuhiro
    Hasegawa, Yoshinori
    Bando, Masashi
    Abe, Shinji
    Mochizuki, Yoshiro
    Chida, Kingo
    Klueglich, Matthias
    Fujimoto, Tsuyoshi
    Okazaki, Kotaro
    Tadayasu, Yusuke
    Sakamoto, Wataru
    Sugiyama, Yukihiko
    EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (05) : 1382 - 1392
  • [4] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    PLOS ONE, 2024, 19 (06):
  • [5] Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis Reply
    Vancheri, Carlo
    Kreuter, Michael
    Richeldi, Luca
    Quaresma, Manuel
    Stowasser, Susanne
    Wuyts, Wim A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (08) : 1105 - 1106
  • [6] A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
    Naqvi, Marium
    D'Ancona, Grainne
    West, Alex
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [7] Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Fell, Charlene D.
    Huggins, J. Terrill
    Nunes, Hilario
    Sussman, Robert
    Valenzuela, Claudia
    Petzinger, Ute
    Stauffer, John L.
    Gilberg, Frank
    Bengus, Monica
    Wijsenbeek, Marlies
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [8] Nintedanib and Pirfenidone as a Bridge to Lung Transplant in Idiopathic Pulmonary Fibrosis
    Li, D.
    Mason, W.
    Hoy, H.
    Robbins, I.
    Loyd, J.
    Lancaster, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [9] Outcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
    Cottin, V.
    Spagnolo, P.
    Bonniaud, P.
    Nolin, M.
    Dalon, F.
    Kirchgassler, K.
    Chia, J.
    Kamath, T. V.
    Van Ganse, E.
    Belhassen, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Outcomes in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
    Cottin, Vincent
    Spagnolo, Paolo
    Bonniaud, Philippe
    Nolin, Maeva
    Dalon, Faustine
    Chia, Jenny
    Kirchgassler, Klaus
    Kamath, Tripthi
    Van Ganse, Eric
    Belhassen, Manon
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 121 - 121
12345